Sirnaomics

Sirnaomics is an international biopharmaceutical company with a mission to develop RNAi and mRNA therapeutics for diseases with significant unmet medical needs. Its key achievement is the landmark positive Phase IIb data for STP705 in cutaneous squamous cell carcinoma in situ, validating its core PNP delivery platform. The company's strategy is built on advancing a diversified pipeline across oncology, fibrosis, and aesthetics, while expanding its technology through strategic partnerships and a dual-track presence in the U.S. and China.

Proprietary Polypeptide Nanoparticle (PNP) delivery for solid tumors and GalNAc conjugation platforms (GalAhead™, PDoV™) for liver-targeted RNAi therapeutics.

Competes with Alnylam and Arrowhead in RNAi, but differentiated by PNP platform for solid tumors. Faces competition in aesthetics from device/pharma companies. Sino-U.S. structure offers efficiency but adds regulatory complexity.